Patents Assigned to Oncolytics Biotech, Inc.
-
Publication number: 20200237917Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.Type: ApplicationFiled: February 13, 2020Publication date: July 30, 2020Applicant: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey
-
Patent number: 10167452Abstract: The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.Type: GrantFiled: February 7, 2014Date of Patent: January 1, 2019Assignee: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey
-
Patent number: 10039827Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.Type: GrantFiled: February 13, 2014Date of Patent: August 7, 2018Assignee: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey
-
Patent number: 9610309Abstract: Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.Type: GrantFiled: April 23, 2015Date of Patent: April 4, 2017Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
-
Patent number: 9610352Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.Type: GrantFiled: April 22, 2015Date of Patent: April 4, 2017Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
-
Patent number: 9365823Abstract: The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.Type: GrantFiled: May 28, 2013Date of Patent: June 14, 2016Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Publication number: 20150224198Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.Type: ApplicationFiled: April 22, 2015Publication date: August 13, 2015Applicant: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
-
Patent number: 9044498Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.Type: GrantFiled: December 2, 2011Date of Patent: June 2, 2015Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
-
Patent number: 9045728Abstract: Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.Type: GrantFiled: December 2, 2011Date of Patent: June 2, 2015Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
-
Publication number: 20140186301Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.Type: ApplicationFiled: February 13, 2014Publication date: July 3, 2014Applicant: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey
-
Publication number: 20140178969Abstract: The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.Type: ApplicationFiled: February 7, 2014Publication date: June 26, 2014Applicant: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey
-
Patent number: 8709443Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: November 2, 2011Date of Patent: April 29, 2014Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 8691241Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.Type: GrantFiled: August 2, 2010Date of Patent: April 8, 2014Assignee: Oncolytics Biotech Inc.Inventor: Matthew C Coffey
-
Patent number: 8685734Abstract: The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.Type: GrantFiled: April 17, 2007Date of Patent: April 1, 2014Assignee: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey
-
Patent number: 8658158Abstract: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.Type: GrantFiled: September 24, 2012Date of Patent: February 25, 2014Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Patent number: 8512712Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.Type: GrantFiled: February 29, 2012Date of Patent: August 20, 2013Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Patent number: 8491886Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.Type: GrantFiled: November 16, 2011Date of Patent: July 23, 2013Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Patent number: 8491884Abstract: The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.Type: GrantFiled: April 6, 2011Date of Patent: July 23, 2013Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Patent number: 8470312Abstract: Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.Type: GrantFiled: May 27, 2009Date of Patent: June 25, 2013Assignee: Oncolytics Biotech, Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson, Hardev Pandha
-
Patent number: 8298785Abstract: The present invention provides a method of detecting adventitious agents in a composition comprising a microorganism by using ribozyme-expressing indicator cells, as well as indicator cells useful in such detection.Type: GrantFiled: February 17, 2010Date of Patent: October 30, 2012Assignee: Oncolytics Biotech Inc.Inventor: Matthew C. Coffey